



NDA 022567/S-019

SUPPLEMENT APPROVAL

Forest Laboratories, LLC
Attention: Nadia C. Success
Manager, Regulatory Affairs
Harborside Financial Center
Plaza V, Suite 1900
Jersey City, NJ 07311

Dear Ms. Success:

Please refer to your Supplemental New Drug Application (sNDA) dated and received August 15, 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Viibryd (vilazodone hydrochloride) 10 mg, 20 mg, and 40 mg tablets..

We also refer to our Safety Labeling Change Notification letters dated May 31, 2016, and June 8, 2016, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for Viibryd (vilazodone). This information pertains to the risk of sleep paralysis and acute pancreatitis.

This supplemental new drug application provides for the addition of sleep paralysis and acute pancreatitis to the **Post-marketing Experience** subsection (6.2) consistent with our May 31, 2016, and June 8, 2016 letters.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please contact CAPT Bill Bender, Senior Regulatory Project Manager, at (301) 796-2145 or via email at William.bender2@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Mitchell Mathis, M.D.
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MITCHELL V Mathis
09/06/2016